Mirador Capital Partners LP Celldex Therapeutics, Inc. Transaction History
Mirador Capital Partners LP
- $529 Million
- Q4 2024
A detailed history of Mirador Capital Partners LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Mirador Capital Partners LP holds 119,492 shares of CLDX stock, worth $2.35 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
119,492
Previous 116,147
2.88%
Holding current value
$2.35 Million
Previous $3.95 Million
23.47%
% of portfolio
0.57%
Previous 0.72%
Shares
20 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$99.5 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$92.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$76.2 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$73.7 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$69.9 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $919M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...